• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

十二指肠溃疡的内科及手术治疗费用。

Costs of medical and surgical treatment of duodenal ulcer.

作者信息

Sonnenberg A

机构信息

Department of Medicine, Veterans Administration Medical Center, Milwaukee, Wisconsin.

出版信息

Gastroenterology. 1989 Jun;96(6):1445-52. doi: 10.1016/0016-5085(89)90511-8.

DOI:10.1016/0016-5085(89)90511-8
PMID:2565844
Abstract

Proximal gastric vagotomy and intermittent and maintenance therapy with H2-antagonists have all been claimed to be effective in long-term management of duodenal ulcer disease. The model of a Markov chain was used to compare their costs by a medical decision analysis. The high price of the initial procedure made proximal gastric vagotomy the most expensive therapy, its costs rising from +10,600 after 1 yr to +12,200 after 15 yr. The average costs of intermittent therapy per patient rose from +500 to +7500. Maintenance therapy cost as much as intermittent therapy but provided 8% and 4% more time spent free of ulcer relapse and pain, respectively. In a sensitivity analysis, the order of the therapeutic options regarding their cost-effectiveness remained robust to changes in the assumptions underlying the model. In a European health care system, the initial surgical procedure cost only one-seventh of the average annual income compared with two-thirds in the United States, and proximal gastric vagotomy turned out to be the cheapest therapy after 6 yr. These results suggest that maintenance therapy provides the best long-term management. Gastric surgery may represent a cost-effective measure of ulcer prevention in Europe but not in the United States.

摘要

近端胃迷走神经切断术以及使用H2拮抗剂进行间歇性和维持性治疗,均被宣称对十二指肠溃疡病的长期管理有效。通过医学决策分析,采用马尔可夫链模型来比较它们的成本。初始手术价格高昂,使得近端胃迷走神经切断术成为最昂贵的治疗方法,其成本从1年后的10,600英镑升至15年后的12,200英镑。每位患者间歇性治疗的平均成本从500英镑升至7500英镑。维持性治疗的成本与间歇性治疗相当,但分别使无溃疡复发和无痛的时间增加了8%和4%。在敏感性分析中,各治疗方案在成本效益方面的排序对模型所依据假设的变化保持稳健。在欧洲医疗体系中,初始外科手术成本仅占平均年收入的七分之一,而在美国则占三分之二,结果显示近端胃迷走神经切断术在6年后成为最便宜的治疗方法。这些结果表明维持性治疗提供了最佳的长期管理。胃手术在欧洲可能是一种具有成本效益的溃疡预防措施,但在美国并非如此。

相似文献

1
Costs of medical and surgical treatment of duodenal ulcer.十二指肠溃疡的内科及手术治疗费用。
Gastroenterology. 1989 Jun;96(6):1445-52. doi: 10.1016/0016-5085(89)90511-8.
2
Comparison of different strategies for treatment of duodenal ulcer.十二指肠溃疡不同治疗策略的比较。
Br Med J (Clin Res Ed). 1985 Apr 20;290(6476):1185-7. doi: 10.1136/bmj.290.6476.1185.
3
Costs of duodenal ulcer therapy with antibiotics.十二指肠溃疡抗生素治疗的费用。
Arch Intern Med. 1995 May 8;155(9):922-8.
4
Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.组胺H2受体拮抗剂维持治疗与幽门螺杆菌根除治疗的决策分析:十二指肠溃疡持续疼痛患者的一项随机对照试验
Pharmacoeconomics. 1999 Oct;16(4):355-65. doi: 10.2165/00019053-199916040-00004.
5
Economic and health aspects of peptic ulcer disease and H2-receptor antagonists.消化性溃疡疾病和H2受体拮抗剂的经济与健康方面
Am J Med. 1986 Oct 24;81(4B):42-8. doi: 10.1016/0002-9343(86)90599-1.
6
A cost analysis of alternative treatments for duodenal ulcer.十二指肠溃疡替代治疗方案的成本分析。
Ann Intern Med. 1995 Nov 1;123(9):665-72. doi: 10.7326/0003-4819-123-9-199511010-00004.
7
[Economic effectiveness of conservative and surgical methods of treatment of duodenal ulcer in young patients].[年轻患者十二指肠溃疡保守治疗与手术治疗方法的经济有效性]
Khirurgiia (Mosk). 1991 Mar(3):14-9.
8
[Clinico-economical effectiveness of conservative and surgical treatment of duodenal ulcer (results of 5-year study)].十二指肠溃疡保守治疗与手术治疗的临床经济学效果(5年研究结果)
Klin Khir (1962). 1989(8):22-4.
9
Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin.使用奥美拉唑联合克拉霉素或阿莫西林进行幽门螺杆菌根除治疗的决策分析。
Pharmacoeconomics. 1996 Jul;10(1):79-92. doi: 10.2165/00019053-199610010-00008.
10
Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.十二指肠溃疡中根除幽门螺杆菌治疗方案的成本效益
Am J Gastroenterol. 1996 Feb;91(2):239-45.

引用本文的文献

1
Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan.反流性食管炎的治疗策略,包括钾离子竞争性酸阻滞剂:日本的成本效益分析
J Gen Fam Med. 2021 Feb 21;22(5):237-245. doi: 10.1002/jgf2.429. eCollection 2021 Sep.
2
Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.沃克帕唑与兰索拉唑用于反流性食管炎初始治疗的比较:日本的成本效益分析
Intern Med. 2019 Sep 1;58(17):2427-2433. doi: 10.2169/internalmedicine.2535-18. Epub 2019 Jun 7.
3
Current medical management of peptic ulcer disease.
当前消化性溃疡病的医学治疗方法。
Can Fam Physician. 1989 Oct;35:2107-10.
4
"Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.质子泵抑制剂优先策略与逐步升级策略用于反流性食管炎急性治疗的比较:日本的成本效益分析
J Gastroenterol. 2005 Nov;40(11):1029-35. doi: 10.1007/s00535-005-1704-y.
5
Cost savings with antacid treatment?使用抗酸剂治疗能节省成本吗?
Pharmacoeconomics. 1993 Feb;3(2):173-5. doi: 10.2165/00019053-199303020-00009.
6
Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.雷尼替丁:对其在酸相关性疾病治疗中应用的药物经济学评价
Pharmacoeconomics. 1994 Jul;6(1):57-89. doi: 10.2165/00019053-199406010-00007.
7
Formulary management of antiulcer drugs: economic considerations.抗溃疡药物的处方集管理:经济考量
Pharmacoeconomics. 1994 Apr;5(4):313-34. doi: 10.2165/00019053-199405040-00006.
8
Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.机构处方集:药物经济学分析与处方集决策的相关性。
Pharmacoeconomics. 1992 Apr;1(4):265-81. doi: 10.2165/00019053-199201040-00004.
9
Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.奥美拉唑:对其在十二指肠溃疡和反流性食管炎治疗中应用的药物经济学评价
Pharmacoeconomics. 1993 Jun;3(6):482-510. doi: 10.2165/00019053-199303060-00008.
10
Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model.幽门螺杆菌根除方案的不同疗效:使用决策分析模型的成本效益研究
BMJ. 1998 May 30;316(7145):1648-54. doi: 10.1136/bmj.316.7145.1648.